JORNAY PM 100 MG
METHYLPHENIDATE HYDROCHLORIDE : 100 MG · DIN 02553023 · KNIGHT THERAPEUTICS INC.
Health Canada status: MARKETED
What is JORNAY PM?
JORNAY PM 100 MG contains METHYLPHENIDATE HYDROCHLORIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02553023, held by KNIGHT THERAPEUTICS INC., supplied as CAPSULE (DELAYED AND EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02553023 |
|---|---|
| Brand name | JORNAY PM |
| Generic / active ingredient | METHYLPHENIDATE HYDROCHLORIDE : 100 MG |
| Manufacturer | KNIGHT THERAPEUTICS INC. |
| Strength | 100 MG |
| Dosage form | CAPSULE (DELAYED AND EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA III) |
| ATC code | N06BA04 METHYLPHENIDATE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Nov-2025 |
What can be used instead?
Other Canadian products sharing ATC code N06BA04 METHYLPHENIDATE. 55 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441934 |
| ACT METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441942 |
| ACT METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441950 |
| ACT METHYLPHENIDATE ER | 54 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441969 |
| APO-METHYLPHENIDATE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02249324 |
| APO-METHYLPHENIDATE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02249332 |
| APO-METHYLPHENIDATE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02273950 |
| APO-METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452731 |
| APO-METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452758 |
| APO-METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452766 |
Who else supplies METHYLPHENIDATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLPHENIDATE appears in 923 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.